FIELD: biotechnology.
SUBSTANCE: humanised antibody against human IFN-α is proposed, obtained based on the murine antibodies ASO-1. Also the therapeutic composition and method of prevention, treatment or diminution of intensity of the symptoms of an autoimmune or inflammatory disease or disorder is considered.
EFFECT: invention may find further application in treatment of IFN-α-related diseases.
13 cl, 13 dwg, 18 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED NEUTRALIZING ANTIBODY TO HUMAN INTERFERON-BETA | 2019 |
|
RU2737466C1 |
| ANTIBODIES RAISED AGAINST α-INTERFERON | 2002 |
|
RU2314317C2 |
| ANTIBODIES TO NKG2A AND THEIR APPLICATIONS | 2007 |
|
RU2499001C2 |
| INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
| ANTIBODIES OF INTERFERON ALFA RECEPTOR 1 AND THEIR APPLICATION | 2005 |
|
RU2412202C2 |
| THEOPHYLLINE ANTIBODIES AND METHODS FOR THEIR APPLICATION | 2013 |
|
RU2630664C2 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
| ANTIBODY BLOCKING AGR2, AND USE THEREOF | 2012 |
|
RU2610665C2 |
| HUMANIZED ANTIBODIES, WHICH RECOGNIZE ALPHA-SINUCLEIN | 2013 |
|
RU2642262C2 |
| IMPROVED ANTIBODIES GDF-8 ANTAGONISTS AND THEIR USE | 2013 |
|
RU2630634C2 |
